search
Back to results

The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions. (DURAVEST)

Primary Purpose

Arterial Occlusive Diseases

Status
Terminated
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
stent
angioplasty
Sponsored by
Cordis Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arterial Occlusive Diseases focused on measuring Peripheral Artery Occlusive Disease

Eligibility Criteria

30 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3, 4 or 5); duration of intermittent claudication (category 1-3) should be at least 6 months The patient should be suitable for percutaneous transluminal angioplasty (PTA) and also for stenting. Exclusion Criteria: Poor aortoiliac or common femoral "inflow", which would be deemed inadequate to support a femoropopliteal bypass graft. Patient having total occlusions or severe stenosis of the iliac artery on the same side must be excluded. Gangrene in index limb (Rutherford category 6).

Sites / Locations

  • AMC

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Cordis SMART™ Nitinol Stent

balloon angioplasty

Outcomes

Primary Outcome Measures

Primary patency.

Secondary Outcome Measures

Technical success defined as a successful access and deployment of the device with recanalization, determined by angiography.
Procedural success defined as successful recanalization, without the occurrence of a SAE.
Procedural complications, defined as any adverse event
Ankle Brachial Index.
Treadmill test.
Restenosis measured by Duplex Ultrasound.
Quality of Life assessment.

Full Information

First Posted
February 7, 2006
Last Updated
February 20, 2009
Sponsor
Cordis Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00289055
Brief Title
The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.
Acronym
DURAVEST
Official Title
A Clinical Investigation of the SMART™ Nitinol Self-Expandable Stent Versus Balloon Angioplasty for the Treatment of Superficial Femoral Artery Occlusions
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Terminated
Why Stopped
lack of enrollment
Study Start Date
November 2005 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Cordis Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of this study is to assess the patency rate of the nitinol self-expandable stent device in the treatment of superficial femoral artery (SFA) occlusions as compared to angioplasty only.
Detailed Description
This is a multi-center prospective, randomized, two-arm study evaluating performance of the Cordis SMART™ nitinol self-expanding stent as compared to balloon angioplasty only. Patients will be randomized on a 1:1 basis. It is anticipated that a total of 120 patients will be entered into the study. The study population will consist of symptomatic peripheral vascular disease patients with SFA occlusions. The disease will consist of symptomatic, long de novo or restenotic occlusions (5 - 14.5 cm) on diagnostic imaging with a history of at least 6 months. The occlusions must not extend beyond the proximal popliteal artery. For the purpose of this protocol, no lesion within 3 cm of the upper part of the patella may be treated. The distal popliteal artery must be patent with no hemodynamic stenosis as well as two calf vessels. Reference vessel diameter must be >= 4.0 to <= 6.0 mm. Trial participants will be randomized to the SMART™ nitinol self-expanding stent or to balloon angioplasty only. Patients will be followed for twelve months post-procedure. Study examinations will be done at screening, procedure time, discharge, six, and twelve months post procedure. This study will be conducted at 8 investigational sites in The Netherlands.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Occlusive Diseases
Keywords
Peripheral Artery Occlusive Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Cordis SMART™ Nitinol Stent
Arm Title
2
Arm Type
Active Comparator
Arm Description
balloon angioplasty
Intervention Type
Device
Intervention Name(s)
stent
Intervention Description
Cordis SMART™ Nitinol Stent
Intervention Type
Device
Intervention Name(s)
angioplasty
Intervention Description
balloon angioplasty
Primary Outcome Measure Information:
Title
Primary patency.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Technical success defined as a successful access and deployment of the device with recanalization, determined by angiography.
Time Frame
at deployment
Title
Procedural success defined as successful recanalization, without the occurrence of a SAE.
Time Frame
up to the moment haemostasis has been achieved
Title
Procedural complications, defined as any adverse event
Time Frame
from start of the procedure up to the moment haemostasis has been achieved
Title
Ankle Brachial Index.
Time Frame
discharge and 12 months
Title
Treadmill test.
Time Frame
12 months
Title
Restenosis measured by Duplex Ultrasound.
Time Frame
12 months
Title
Quality of Life assessment.
Time Frame
baseline, 6, and 12 months post procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3, 4 or 5); duration of intermittent claudication (category 1-3) should be at least 6 months The patient should be suitable for percutaneous transluminal angioplasty (PTA) and also for stenting. Exclusion Criteria: Poor aortoiliac or common femoral "inflow", which would be deemed inadequate to support a femoropopliteal bypass graft. Patient having total occlusions or severe stenosis of the iliac artery on the same side must be excluded. Gangrene in index limb (Rutherford category 6).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jim Reekers, MD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
AMC
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.

We'll reach out to this number within 24 hrs